Results 221 to 230 of about 88,519 (382)

Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease.

Circulation, 1997
R. Boger, S. Bode-Boger, W. Thiele, Wolfgang Junker, K. Alexander, J. C. Frolich, Rainer H Bbger   +6 more
semanticscholar   +1 more source

Anti‐inflammatory effects of physical stimuli: The central role of networks in shaping the future of pharmacological research

British Journal of Pharmacology, EarlyView.
Addressing complexity in the study of life sciences through Systems Biology and Systems Medicine has been transformative, making Systems Pharmacology the next logical step. In this review, we focus on physical stimuli, whose potential in pharmacology has been neglected, despite demonstrated therapeutic properties.
Veronica Paparozzi, Reyhaneh Hooshmandabbasi, Alessandro Ravoni, Ying Ma, Luigi Manni, Timothy J. Koh, Caroline Maake, Tiziana Guarnieri, Darong Lai, Vitalii Zablotskii, Christine Nardini   +10 more
wiley   +1 more source

Determinants of Peak V.O2 in Peripheral Arterial Occlusive Disease Patients [PDF]

, 2000
A. S. Ryan, Leslie I. Katzel, Andrew W. Gardner   +2 more
openalex   +1 more source

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis

Leukemia, 2013
F. Giles, M. Mauro, F. Hong, C. Ortmann, C. McNeill, R. Woodman, A. Hochhaus, P. Coutre, G. Saglio   +8 more
semanticscholar   +1 more source

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

British Journal of Pharmacology, EarlyView.
Psychedelic drugs that activate 5‐HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti‐inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune
Omar Qureshi, Jamie Cowley, Ashley Pegg, Alison J. Cooper, John Gordon, Catherine A. Brady, Antonio Belli, Sam Butterworth, Rachel Upthegrove, Nick Andrews, Nicholas M. Barnes   +10 more
wiley   +1 more source

Telephone Health Coaching and Remote Exercise Monitoring (TeGeCoach) in Peripheral Arterial Occlusive Disease—a Randomized Controlled Trial. [PDF]

Dtsch Arztebl Int
Rezvani F, Heider D, König HH, Herbarth L, Steinisch P, Schuhmann F, Böbinger H, Krack G, Korth T, Thomsen L, Chase DP, Schreiber R, Alscher MD, Finger B, Härter M, Dirmaier J.   +15 more
europepmc   +1 more source

Effect of cilostazol on claudication distances and lipid profile in patients with occlusive peripheral arterial disease: A placebo controlled trial

, 2017
Surjeet Singh
openalex   +1 more source

Response to Comment on ‘Stem-cell Therapy for Peripheral Arterial Occlusive Disease’ [PDF]

, 2012
Dongik Kim
openalex   +1 more source

Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease.

Circulation, 1989
M. Malinow, S. S. Kang, L. Taylor, P. Wong, B. Coull, T. Inahara, D. Mukerjee, G. Sexton, B. Upson   +8 more
semanticscholar   +1 more source

Leveraging the ADAM10 prodomain for selective inhibition to enhance recovery after myocardial infarction

British Journal of Pharmacology, EarlyView.
Background and Purpose Inflammation plays a crucial role in the development and progression of numerous acute and chronic diseases such as myocardial infarction (MI) and heart failure. Targeting ADAM proteases, particularly ADAM10, holds promise for fine‐tuning inflammatory responses.
Erik Klapproth, Johanna Marks, Patrick Diaba‐Nuhoho, Sören Grell, Paul Leubauer, Susanne Kämmerer, Johannes R. Soltwedel, Fred Rasmussen, Felix Mejia, Marcia L. Moss, Christopher Prince, Peter Mirtschink, Ben Wielockx, Paul Saftig, Michael Wagner, Kristina Lorenz, Ali El‐Armouche   +16 more
wiley   +1 more source